Concepts (58)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2008 | 5 | 0.280 |
Why?
|
| Cachexia | 2 | 2019 | 8 | 0.280 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2019 | 10 | 0.280 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2017 | 7 | 0.220 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2017 | 35 | 0.210 |
Why?
|
| Thrombosis | 1 | 2021 | 16 | 0.170 |
Why?
|
| Graft vs Host Disease | 1 | 2020 | 28 | 0.150 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2020 | 34 | 0.150 |
Why?
|
| Medical Oncology | 1 | 2018 | 10 | 0.140 |
Why?
|
| Cardiology | 1 | 2018 | 13 | 0.140 |
Why?
|
| Humans | 7 | 2021 | 5837 | 0.120 |
Why?
|
| Female | 5 | 2019 | 3346 | 0.100 |
Why?
|
| Middle Aged | 4 | 2017 | 1775 | 0.100 |
Why?
|
| Hemoglobinuria, Paroxysmal | 1 | 2012 | 1 | 0.090 |
Why?
|
| Male | 4 | 2019 | 3399 | 0.090 |
Why?
|
| Fatal Outcome | 1 | 2008 | 10 | 0.070 |
Why?
|
| Weight Loss | 2 | 2019 | 45 | 0.070 |
Why?
|
| Prognosis | 2 | 2019 | 138 | 0.070 |
Why?
|
| Retrospective Studies | 2 | 2019 | 584 | 0.060 |
Why?
|
| Aged, 80 and over | 1 | 2008 | 1034 | 0.060 |
Why?
|
| Proto-Oncogenes | 1 | 2004 | 2 | 0.050 |
Why?
|
| Thalidomide | 1 | 2004 | 2 | 0.050 |
Why?
|
| Arsenicals | 1 | 2004 | 5 | 0.050 |
Why?
|
| Oxides | 1 | 2004 | 5 | 0.050 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2004 | 4 | 0.050 |
Why?
|
| Transcription Factors | 1 | 2004 | 61 | 0.050 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2004 | 22 | 0.050 |
Why?
|
| Antineoplastic Agents | 1 | 2004 | 48 | 0.050 |
Why?
|
| DNA-Binding Proteins | 1 | 2004 | 94 | 0.050 |
Why?
|
| Treatment Outcome | 2 | 2019 | 601 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 187 | 0.040 |
Why?
|
| Transplantation, Homologous | 1 | 2020 | 38 | 0.040 |
Why?
|
| Sarcopenia | 1 | 2019 | 8 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2019 | 37 | 0.040 |
Why?
|
| Body Composition | 1 | 2019 | 31 | 0.040 |
Why?
|
| Sex Factors | 1 | 2019 | 129 | 0.040 |
Why?
|
| Neoplasms | 1 | 2019 | 39 | 0.040 |
Why?
|
| Cardiologists | 1 | 2018 | 1 | 0.040 |
Why?
|
| Interdisciplinary Communication | 1 | 2018 | 5 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2019 | 406 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 30 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 71 | 0.030 |
Why?
|
| Adult | 1 | 2021 | 1670 | 0.030 |
Why?
|
| Vincristine | 1 | 2012 | 6 | 0.020 |
Why?
|
| Rituximab | 1 | 2012 | 4 | 0.020 |
Why?
|
| Prednisone | 1 | 2012 | 7 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2012 | 4 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2012 | 11 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2012 | 14 | 0.020 |
Why?
|
| MDS1 and EVI1 Complex Locus Protein | 1 | 2004 | 2 | 0.010 |
Why?
|
| Cell Lineage | 1 | 2004 | 9 | 0.010 |
Why?
|
| Zinc Fingers | 1 | 2004 | 8 | 0.010 |
Why?
|
| Spleen | 1 | 2004 | 7 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 37 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2004 | 35 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2004 | 17 | 0.010 |
Why?
|
| Risk Factors | 1 | 2004 | 499 | 0.010 |
Why?
|
| Aged | 1 | 2004 | 1860 | 0.010 |
Why?
|